Enrollment Commenced in Barnabas Health and Champions Oncology Breast Cancer Research Trial

Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, in conjunction with Barnabas Health, successfully enrolled the first patient in a groundbreaking breast cancer research trial.

The research trial is designed to validate the predictability and utility of the Champions TumorGraft™ platform in various types of breast cancer and will provide greater insight into personalized cancer therapy. 30 patients are expected to enroll in the study.

Following a procedure conducted at Monmouth Medical Center in Long Branch, NJ, the patient's tumor was successfully implanted in a mouse avatar model utilizing Champions' TumorGraft™ platform for personalized cancer therapy . Upon enrollment in the research trial, current and future trial participants will receive TumorGraft implanting, testing and recommendations.

Inclusion in the clinical trial is open to patients requiring surgical removal of a malignant breast tumor, and must meet one of the following criteria:

Breast cancer that has spread (metastasized) to a different part of the body

The tumor initially tested negative for ER, PR, and HER2

The tumor initially tested positive for HER2

The tumor was treated with chemotherapy prior to surgery and remains malignant

For more information on the trial or to apply to participate, contact Kimberly Chow at the Leon Hess Cancer Center's Oncology Clinical Research Program, 732-923-6564.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.

This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.